

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF CALIFORNIA  
SAN FRANCISCO DIVISION**

IN RE: ROUNDUP PRODUCTS  
LIABILITY LITIGATION

MDL No. 2741  
Case No. 16-md-02741-VC

This document relates to:

Hon. Vince Chhabria

*Hardeman v. Monsanto Co., et al.*,  
3:16-cv-0525-VC  
*Stevick v. Monsanto Co., et al.*, 3:16-  
cv-2341-VC  
*Gebeyehou v. Monsanto Co., et al.*,  
3:16-cv-5813-VC

**PLAINTIFFS' OPPOSITION TO ISSUE  
BIFURCATION**

**TABLE OF CONTENTS**

	Page
TABLE OF CONTENTS.....	i
TABLE OF AUTHORITIES .....	ii
INTRODUCTION .....	1
LEGAL STANDARD.....	1
ARGUMENT.....	2
I.    Bifurcating a Trial Around a Defendant’s Favored Defense in the Context of a Bellwether Trial Undermines the Purpose of a Bellwether Trial .....	2
II.   Monsanto Has Not Established Why Bifurcation Is Justified .....	7
A.   Monsanto Presents No Evidence, Beyond Bald Assertions, that a Typical Trial Would Prejudice Monsanto.....	7
B.   Bifurcation on Causation Creates Structural and Substantive Prejudice .....	9
C.   Separating Probative Causation Evidence from Probative Liability Is Nearly Impossible.....	10
•    The Credibility of Monsanto-Generated Science: .....	10
•    Monsanto’s Admissions:.....	11
•    Monsanto’s Manipulation of Science: .....	12
•    Credibility of Plaintiffs’ Experts:.....	14
•    Plaintiffs’ Treating Doctors: .....	14
D.   Bifurcation Defies Judicial Efficiency and Economy.....	15
CONCLUSION.....	15

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**TABLE OF AUTHORITIES**

Page(s)

**Cases**

*Adams v. Cooper Indus., Inc.*,  
 No. CIV.A. 03-476-JBC, 2007 WL 1075647 (E.D. Ky. Apr. 4, 2007).....9

*Bates v. United Parcel Service*,  
 204 F.R.D. 440 (N.D. Cal. 2001).....7

*Broad v. N. Pointe Ins. Co.*,  
 No. 5:11CV2422, 2012 WL 12894227 (N.D. Ohio Aug. 30, 2012) .....2

*Collazo v. WEN by Chaz Dean, Inc.*,  
 No. 215CV01974ODWAGR, 2018 WL 3424957 (C.D. Cal. July 12, 2018) .....2

*GEM Acquisitionco, LLC v. Sorenson Grp. Holdings, LLC*,  
 No. C 09–01484 SI, 2010 WL 1729400 (N.D. Cal. Apr. 27, 2010).....2

*Gravity Defyer Corp. v. Under Armour, Inc.*,  
 No. LACV1301842JAKJCGX, 2013 WL 12138987 (C.D. Cal. July 23, 2013).....2, 7

*Hangarter v. Provident Life and Assoc. Ins. Co.*,  
 373 F.3d 998 (9th Cir. 2004) .....2

*In re “Agent Orange” Prod. Liab. Litig.*,  
 611 F. Supp. 1223 (E.D.N.Y. 1985) .....9

*In re Bendectin Litig.*,  
 857 F.2d 290 (6th Cir. 1988) .....5, 6

*In re Beverly Hills Fire Litig.*,  
 695 F.2d 207 (6th Cir. 1982). .....5, 6, 8

*In re Diet Drugs (Phentermine/Fenfluramine/ Dexfenfluramine) Prod. Liab. Litig.*,  
 123 F. App’x 465 (3d Cir. 2005) .....4

*In re Hanford Nuclear Reservation Litig.*,  
 534 F.3d 986 (9th Cir. 2008) .....2

1 *In re Heparin Prod. Liab. Litig.*,

2 No. 1:08HC60000, 2011 WL 1097637 (N.D. Ohio Mar. 22, 2011) .....3, 6, 7, 9

3 *In re New York Cty. DES Litig.*,

4 211 A.D.2d 500 (1995).....4

5 *In re Prempro Prod. Liab. Litig.*,

6 586 F.3d 547 (8th Cir. 2009) .....5

7 *In re Rhone-Poulenc Rorer, Inc.*,

8 51 F.3d 1293 (7th Cir. 1995) .....5

9 *In re Sortwell, Inc.*,

10 No. C 08-05167 JW, 2011 WL 4896475 (N.D. Cal. Oct. 12, 2011) .....1, 2

11 *Jenkins v. Raymark Industries, Inc.*,

12 782 F.2d 468 (5th Cir. 1986) .....3, 12

13 *MySpace, Inc. v. Graphon Corp.*,

14 732 F. Supp. 2d 915 (N.D. Cal. 2010).....9

15 *Nye v. Ingersoll Rand Co.*,

16 No. CIV. 08-3481 DRD, 2011 WL 4017741 (D.N.J. Sept. 8, 2011) .....3

17 *Simon v. Philip Morris Inc.*,

18 200 F.R.D. 21 (E.D.N.Y.2001).....3

19 *Spectra–Physics Lasers, Inc. v. Uniphase Corp.*,

20 144 F.R.D. 99 (N.D. Cal. 1992).....2, 7

21 *STC UNM v. Intel Corp.*,

22 No. 10-CV-1077 RB/WDS, 2011 WL 7562686 (D.N.M. Dec. 22, 2011) .....3

23 *United Air Lines, Inc. v. Wiener*,

24 286 F.2d 302 (9th Cir. 1961). .....5

25 **Rules**

26 Fed. R. Civ. P. 42 .....1

27 **Treatises**

28 MANUAL FOR COMPLEX LITIGATION (Fourth) § 22.315 (2004) .....2

## INTRODUCTION

1  
2 The type of reverse bifurcation proposed by Monsanto—where the defendant is permitted to  
3 have a trial on its favored defense before reaching any other issue—is unheard of in the modern MDL  
4 bellwether process. Indeed, Monsanto has not and cannot cite any MDL implementing such an  
5 approach for a bellwether trial. It is simply never done, and for good reason. The purpose of a  
6 bellwether trial is to allow each side to test their theories and evidence against a real-world jury and,  
7 hopefully, learn important information about the strengths and weaknesses of the case to inform  
8 collective resolution. Imposing a one-sided procedural hurdle—one that would be a *de facto* outlier  
9 for the 10,000 cases proceeding around the country—does not accomplish that goal. It renders any  
10 verdict in this MDL, no matter which side prevails, unhelpful.

11 The bifurcation Monsanto proposes also fails under the law. Under Rule 42, bifurcation  
12 should not be permitted if it will prejudice the non-moving party or if the issues to be bifurcated are  
13 inseparable. Here, Monsanto’s proposed bifurcation would create structural and substantive  
14 prejudice against Plaintiffs, discussed in detail below. Even Monsanto acknowledges in its Seventh  
15 Amendment jury discussion, *see* Mot. At 9-10, that both trial phases would have to be tried by the  
16 same jury because each phase is sufficiently overlapping that the Seventh Amendment would prohibit  
17 different juries hearing the different parts. It would also be, as a practical matter, impossible to  
18 separate evidence that is probative of causation from evidence that is probative of liability. There is  
19 simply too much overlap in light of Monsanto’s pervasive manipulation, fabrication, and intimidation  
20 of the very science underlying causation.

21 There are circumstances where bifurcation on a specific issue makes sense, albeit it is the rare  
22 exception. This is not one of those circumstances. Indeed, if anything, these bellwether cases should  
23 be treated as “typical” as possible. This case has already been bifurcated once, over Plaintiffs’  
24 objection, and there is no benefit to bifurcating it again when the same jury would have to hear each  
25 phase. Plaintiffs oppose bifurcating the Group 1 bellwether trials.

## LEGAL STANDARD

26  
27 “In the Ninth Circuit, ‘[b]ifurcation ... is the exception rather than the rule[.]’” *In re Sortwell,*  
28 *Inc.*, No. C 08-05167 JW, 2011 WL 4896475, at \*2 (N.D. Cal. Oct. 12, 2011) (quoting *GEM*

1 *Acquisitionco, LLC v. Sorenson Grp. Holdings, LLC*, No. C 09–01484 SI, 2010 WL 1729400, at \*3  
 2 (N.D. Cal. Apr. 27, 2010)); *see Hangarter v. Provident Life and Assoc. Ins. Co.*, 373 F.3d 998, 1021  
 3 (9th Cir. 2004) (Trying issues together is “normal trial procedure.”). And rightly so—“[i]n general, a  
 4 single proceeding will be a more efficient and reasonable means of resolving the action.” *Gravity*  
 5 *Defyer Corp. v. Under Armour, Inc.*, No. LACV1301842JAKJCGX, 2013 WL 12138987, at \*2 (C.D.  
 6 Cal. July 23, 2013). This why the Advisory Committee specifically cautions that “separation of  
 7 issues for trial is not to be routinely ordered[.]” Fed. R. Civ. P. 42 advisory committee’s note (1966).

8 Thus, while Monsanto is correct that the decision to order bifurcation is discretionary, it  
 9 should only be ordered when justified—that is, when bifurcation promotes “convenience ... avoid[s]  
 10 prejudice, or ... expedite[s] and economize[s].” Fed. R. Civ. P. 42. And, importantly, the party  
 11 seeking bifurcation “has the burden of proving that bifurcation is justified.” *Sortwell*, 2011 WL  
 12 4896475, at \*2 (quoting *Spectra–Physics Lasers, Inc. v. Uniphase Corp.*, 144 F.R.D. 99, 101 (N.D.  
 13 Cal. 1992)). Unsubstantiated claims of jury confusion, prejudice, or efficiency are not enough. *E.g.*,  
 14 *Broad v. N. Pointe Ins. Co.*, No. 5:11CV2422, 2012 WL 12894227, at \*1 (N.D. Ohio Aug. 30, 2012)  
 15 (“Simply complaining of prejudice without producing evidence ... is not sufficient.”).

## 16 ARGUMENT

### 17 **I. Bifurcating a Trial Around a Defendant’s Favored Defense in the Context of a** 18 **Bellwether Trial Undermines the Purpose of a Bellwether Trial**

19 Before delving into the factors the Court should weigh in deciding whether to bifurcate, there  
 20 is an overriding practical consideration this Court should consider. A bellwether trial is supposed “to  
 21 produce reliable information about other mass tort cases.” MANUAL FOR COMPLEX  
 22 LITIGATION (Fourth) § 22.315 (2004). Specifically, “[b]ellwether trials can guide future settlement  
 23 negotiations by showing how similar claims may fare before juries.” *Collazo v. WEN by Chaz Dean,*  
 24 *Inc.*, No. 215CV01974ODWAGR, 2018 WL 3424957, at \*2 (C.D. Cal. July 12, 2018); *see In re*  
 25 *Hanford Nuclear Reservation Litig.*, 534 F.3d 986, 995 (9th Cir. 2008) (Bellwether “trial was  
 26 designed to produce a verdict that would highlight the strengths and weaknesses of the parties’  
 27 respective cases and ... promote settlement[.]”). Thus, for a bellwether to mean anything in the  
 28 context of an MDL, the trial should approximate what one would expect in a “normal trial  
 procedure.” *Hangarter*, 373 F.3d at 1021. Otherwise, there is no practical value of a verdict, one

1 way or the other. Reverse bifurcation is anything but normal; it is “extraordinary” and “drastic.” *Nye*  
2 *v. Ingersoll Rand Co.*, No. CIV. 08-3481 DRD, 2011 WL 4017741, at \*3 (D.N.J. Sept. 8, 2011).  
3 This is especially true when bifurcation is on an issue that is the defendant’s favorite defense.

4 If this Court elects to bifurcate the specific issue of causation, then these bellwether cases—  
5 the only three available to this Court because of Monsanto’s refusal to waive *Lexicon*—lose their  
6 precedential value. For Plaintiffs *and* Monsanto, any verdict—whether in favor of Plaintiff or  
7 Monsanto—will be discounted because of this unorthodox procedure. The logic behind this is  
8 obvious. “‘Reverse bifurcation’ originated in the Third Circuit as a means of processing that circuit’s  
9 backlog of asbestos-related cases.” *Jenkins v. Raymark Industries, Inc.*, 782 F.2d 468, 473 n. 8 (5th  
10 Cir. 1986). It only makes sense, as it did in asbestos, when the parties “have excellent information  
11 about the likelihood of success on the issue of liability and the real sticking points are the individual  
12 issues of causation and damages.” *Simon v. Philip Morris Inc.*, 200 F.R.D. 21, 32 (E.D.N.Y.2001).  
13 That is not the case here. “Liability in this case is a hotly-contested issue” and “there is nothing to  
14 suggest [Monsanto] has any intention of abandoning its defenses.” *STC UNM v. Intel Corp.*, No. 10-  
15 CV-1077 RB/WDS, 2011 WL 7562686, at \*2 (D.N.M. Dec. 22, 2011). Absent a verdict on *all*  
16 defenses, *tried together*, the Parties will not be aided, for the 10,000+ cases nationwide, in moving  
17 toward resolution. *E.g., In re Heparin Prod. Liab. Litig.*, No. 1:08HC60000, 2011 WL 1097637, at  
18 \*4 (N.D. Ohio Mar. 22, 2011) (rejecting bifurcation on the issue of causation for first bellwether  
19 trials because, in part, “for the bellwether process to be of any real use, jury verdicts as to all  
20 contested issues appear desirable.”).

21 Monsanto cites cases where reverse bifurcation was utilized. But, these cases are the  
22 exception, *not* the rule, and all of them occurred after years of litigation and/or settlements, or  
23 involved unique circumstances.

- 24 • **Asbestos:** In asbestos, as discussed above, reverse bifurcation emerged as a way to promote  
25 settlement by front-loading causation and damages, where liability was largely resolved by  
26 numerous prior trials. *See STC*, 2011 WL 7562686, at \*2.
- 27 • **DES:** The DES (diethylstilbestrol) case cited by Monsanto occurred after thirty years of DES  
28 litigation, including trials, where the reviewing court addressed the issue in one sentence. *See*

1 *In re New York Cty. DES Litig.*, 211 A.D.2d 500, 500 (1995). Similar to the asbestos  
2 situation, the courts did not employ reverse bifurcation in DES cases until many trials  
3 occurred; reverse bifurcation was not employed at the beginning of the litigation..

- 4 • **Diet Drugs:** In the Diet Drug cases, Monsanto lists two federal and fifteen state court  
5 proceedings where courts elected to reverse-bifurcate the trials. But, those cases were tried  
6 after the entry of class wide settlement, where opt out plaintiffs were permitted to seek trial in  
7 state court, provided, they were “ENJOINED from arguing to the state trial court that the  
8 reverse bifurcation procedure or jury instruction that they stipulated to ... should not be used.”  
9 *In re Diet Drugs (Phentermine/Fenfluramine/ Dexfenfluramine) Prod. Liab. Litig.*, 123 F.  
10 App’x 465, 472 (3d Cir. 2005). And, “[i]f asked by the state trial court whether reverse  
11 bifurcation is appropriate, advisable or should otherwise be implemented, plaintiffs, their  
12 agents, attorneys and derivative claimants must answer ‘I am directed by the United States  
13 District Court for the Eastern District of Pennsylvania to stipulate to the use of a reverse  
14 bifurcated trial and I am not permitted to argue or otherwise make statements against this  
15 court’s discretionary use of that procedure.’” *Id.* Looking to those cases as evidence that  
16 reverse bifurcation is common, or even advisable, is misleading and inaccurate.
- 17 • **Hormone Replacement Therapy:** Monsanto cites to a few hormone replacement therapy  
18 cases tried in Philadelphia City Court, where a judge elected to trifurcate the jury trials.  
19 These orders were apparently entered by the same judge, who explained that he had a  
20 personal preference for reverse bifurcation as “the appropriate way to go,” and routinely  
21 required it. *See* Monsanto’s Exh. 4 at pg. 9-10 of 12 (discussing his general rule for reverse  
22 bifurcation); Monsanto’s Exh. 3 at pg. 5-7 of 9 (*sua sponte* ordering reverse bifurcation,  
23 without notice to either party because that is what he normally does). In other words, these  
24 Philadelphia orders reflect the opposite application of law—where reverse bifurcation is the  
25 rule, and regular trials are the exception. This incorrect application of the law, led the Court  
26 to change its rules to prevent reverse bifurcation absent consent of both parties. Gen. Court  
27 Regulation No. 2012-01 at 2, *In re: Mass Tort & Asbestos Programs* (C.P. Phila. Cty. Feb.  
28 15, 2012), available at <https://www.courts.phila.gov/pdf/regs/2012/cpajgr2012-01.pdf>.



1 Tellingly, the MDL proceeding involving these hormone replacement drugs did *not* bifurcate  
2 causation. *See In re Prempro Prod. Liab. Litig.*, 586 F.3d 547, 553 (8th Cir. 2009) (noting  
3 liability and causation were tried together).

- 4 • **Beverly Hills Fire:** In *In re Beverly Hills Fire Litig.*, the Sixth Circuit affirmed a trial court’s  
5 decision to bifurcate the issue of causation. 695 F.2d 207, 216-17 (6th Cir. 1982). But the  
6 circumstances of that case were unique, involving “a class action on behalf of approximately  
7 200 persons against 23 defendants who have been grouped together” and centered around  
8 whether a specific aluminum wire malfunctioned and caused the fire that harmed all the  
9 plaintiffs—a causation trial that, itself, took thirty-two days. *Id.* at 216, n.14. The bifurcated  
10 trial was designed to try the issue of causation for everyone, not just a single bellwether, and  
11 was specifically designed to “enhance the likelihood of settlement[.]” *Id.* And, it was  
12 *because* of these facts that the court did not find an abuse of discretion.
- 13 • **Bendectin:** *In re Bendectin Litig.*, 857 F.2d 290, 309 (6th Cir. 1988) is a thirty-year-old relic  
14 of a time when MDL courts experimented with consolidated trials on common issues. In  
15 *Bendectin*, the district court consolidated 818 cases and ordered a trial on general causation  
16 for all cases. *Id.* at 295. Under this approach, the verdict would bind all parties in the 818  
17 cases, with separate resolution of individual issues to be resolved by different juries. *Id.* This  
18 approach has fallen into disfavor and violates the Seventh Amendment. *See, e.g., In re*  
19 *Rhone-Poulenc Rorer, Inc.*, 51 F.3d 1293, 1303-04 (7th Cir. 1995) (holding that consideration  
20 of liability and damages issues by two different juries violates the Seventh Amendment); *see*  
21 *United Air Lines, Inc. v. Wiener*, 286 F.2d 302, 304, 306 (9th Cir. 1961), *cert. denied*, 366  
22 U.S. 924 (1961).

23 Considering the thousands of mass tort dockets that have been litigated over the last thirty  
24 years, Monsanto’s inability to cite a single example of an MDL bifurcating on the issue of causation  
25 for early bellwether trials is a reflection of how ill-advised and unorthodox the procedure is. It is just  
26 not done in MDL mass torts. This point is underscored by the nature of Monsanto’s proposed  
27 bifurcation. Monsanto is asking to have a trial to exclusively address Monsanto’s favorite defense—  
28 general and specific causation—and to do so in a sterile, artificial courtroom, completely detached

1 from any evidence relating to Monsanto’s wrongful conduct, IARC, or any explanation as to why  
2 Roundup has managed to be on the market for over forty years without a carcinogenicity warning.  
3 Such an exercise is not only fundamentally unfair but, for the purposes of case evaluation, it would be  
4 ignored.

5 The most recent attempt by an MDL defendant to invoke bifurcation on causation for a  
6 bellwether was in *In re Heparin Prod. Liab. Litig.*, No. 1:08HC60000, 2011 WL 1097637, at \*2-4  
7 (N.D. Ohio Mar. 22, 2011). And there, the MDL court correctly rejected it. In *Heparin*, like  
8 Monsanto here, the defendants sought to “divide the bellwether trials into two phases” where the  
9 “first phase would address whether the plaintiff was exposed to contaminated heparin, whether that  
10 exposure caused that plaintiffs’ injuries, and compensatory damages” and the “second phase would  
11 address the defendants’ liability, punitive damages and any other legal issues.” *Id.* at \*2. And, like  
12 Monsanto here, the defendants cited the asbestos cases, *Beverly Hills Fire*, and *Bendectin*, arguing  
13 that “this division will serve judicial economy ... prevent introduction of irrelevant and unfairly  
14 prejudicial evidence about the defendants’ culpable conduct during the causation phase of the trial”  
15 and “avoid presentation of a substantial amount of evidence relating to liability and reduce the time  
16 and costs related to pretrial disputes about the evidence.”<sup>1</sup> *Id.*

17 In rejecting this argument, the MDL court stated first that “causation and liability are neither  
18 separate and distinct issues nor readily severable” and, thus, attempting to bifurcate was not possible.  
19 *Id.* The court recognized the simple fact that, unlike bifurcation between liability and damages, in  
20 situations where there is an obvious and natural division of evidence, parsing evidence related to  
21 liability and causation is near impossible in most cases. Most evidence is probative of both elements.  
22 Second, the MDL court held that “the interests of judicial economy will not be served by bifurcation”  
23 because even “[a] verdict for defendant on causation in one case will not dispose of the issue of  
24 liability in all cases[.]” *Id.* The MDL Court explained that:

25 Circumstances here are quite unlike those in the cases defendants cite in support of  
26 bifurcation. There courts addressed general causation and disposed of litigation  
27 wholesale because the verdicts were binding on all plaintiffs. ... In this case,  
28 however, defendants are not proposing a single, consolidated trial to dispose of the

<sup>1</sup> In *Heparin*, the defendants also claimed the bifurcation process would promote settlement. Monsanto, however, does not take that position here. *Heparin*, 2011 WL 1097637, at \*2.

1 litigation wholesale. Rather, defendants propose bifurcating each bellwether trial  
2 into two phases. Even if this approach potentially might save time and money, it is  
3 not likely to have the cumulative effect that motivated bifurcation in the cases noted  
4 above.

5 *Id.* at \*3-4. Third, the MDL court noted that bellwether cases need to be tried on all defenses if they  
6 are going to offer information to the parties to drive settlement. *Id.* at \*4. Finally, the MDL Court  
7 noted that “any potential for prejudice to defendants can be avoided with appropriate limiting  
8 instructions.” *Id.* The *Heparin* court correctly realized that bifurcating the issue of causation and  
9 liability did not promote efficiency, especially in the context of a bellwether trial. These practical  
10 considerations, by themselves, counsel against engaging in the type of bifurcation proposed by  
11 Monsanto.

## 12 **II. Monsanto Has Not Established Why Bifurcation Is Justified**

13 “Factors to be considered when determining whether to bifurcate include: avoiding prejudice,  
14 separability of the issues, convenience, judicial economy, and reducing risk of confusion.” *Bates v.*  
15 *United Parcel Service*, 204 F.R.D. 440, 448 (N.D. Cal. 2001). Monsanto “has the burden of proving  
16 that bifurcation is justified given the facts in this case[.]” *Spectra-Physics*, 144 F.R.D. at 101. Here,  
17 none of the factors supports bifurcating the case between the issues of causation and liability.

### 18 **A. Monsanto Presents No Evidence, Beyond Bald Assertions, that a Typical Trial Would 19 Prejudice Monsanto**

20 Taken to its logical conclusion, Monsanto’s approach would have all product liability cases  
21 against large corporate defendants bifurcated between causation and liability. Monsanto fails to  
22 explain why *this* case, as opposed to every other product liability case tried in California or  
23 elsewhere, should be treated differently. Its argument is generic: “bifurcation would avoid the risk  
24 that the jury becomes distracted or misled by extraneous evidence of corporate conduct or by the  
25 complex regulatory record.” Mot. at 7. But, corporate conduct and regulatory history are part of all  
26 products cases. And yet, the type of bifurcation envisioned by Monsanto is almost never done. This  
27 is because the proper way to address potential juror confusion—as done in nearly all cases—is to  
28 instruct the jury, not alter the way trials are conducted. *E.g.*, *Gravity Defyer*, 2013 WL 12138987, at  
\*3 (“As to Defendants’ suggestion of jury confusion in a liability and damages trial, jury instructions  
are adequate to address this issue, which is presented in almost every civil action.”). Trying

1 causation along with liability is an important part of the trial process; without it “[t]here is a danger  
2 that bifurcation may deprive plaintiffs of their legitimate right to place before the jury the  
3 circumstances and atmosphere of the entire cause of action which they have brought into the court,  
4 replacing it with a sterile or laboratory atmosphere in which causation is parted from the reality of  
5 injury.” *Beverly Hills Fire*, 695 F.2d at 217.

6 This Court recently acknowledged the ability of jurors to follow instructions and take their  
7 obligations seriously. That is exactly what happened in the *Johnson* case, a point underscored by the  
8 questions asked by the jurors during trial.<sup>2</sup> Exh. 1, Juror Questions, *Johnson v. Monsanto*. These  
9 questions were technical—focused on the underlying science and other scientific issues:

- 10 • “In animal studies, how is glyphosate formulated? What is the vehicle?” *Id.* at 1.
- 11 • “Clarify glyphosate method of action? Does it bind to the enzyme making it  
12 nonfunctional? Does it compete with another substance?” *Id.*
- 13 • “How are micronuclei related to cancer? Supporting data?” *Id.*
- 14 • “In De Roos 2005 study, is it known what the exposure is? ... Same for NAPP,  
15 what are the exposures? Acute/chronic/mix?” *Id.* at 2.
- 16 • “What were the controls in “Genetic Potential of Glyphosate Formulation”  
17 publication which included D. Farmer + Heydens?” *Id.* at 6.
- 18 • “CD1 mice—are these mice more prone to cancer than other strains?” *Id.* at 9.
- 19 • “Were control animals given vehicle solvent alone? Were they given what  
20 glyphosate was dissolved in?” *Id.*
- 21 • “How would AHS numbers/results (RR) be affected if a percentage of those who  
22 have responded passed away from some form of NHL?” *Id.* at 11.
- 23 • “What is the general progression and timeframe of NHL? Are there different  
24 stages? How long does a patient typically start manifesting NHL before it is  
25 diagnosed?” *Id.* at 12.

26 These questions demonstrate that the jury, despite hearing evidence of corporate conduct and  
27 regulatory history, were fully capable of evaluating the scientific issues with impartiality.

28 The only specific “prejudice” identified by Monsanto centers on the International Agency for  
Research on Cancer (“IARC”) and the EPA. Mot. At 6-7. It is undisputed that IARC and EPA are  
relevant to causation—even if, by themselves, they are not dispositive.<sup>3</sup> PTO No. 15 at 2 (“[T]he

<sup>2</sup> The jurors in the *Johnson* trial were permitted to submit written questions to the court and, with the court’s permission, those questions were answered by the testifying witness.

<sup>3</sup> For example, the IARC determination lends credibility to Plaintiffs’ experts’ opinions, provides important peer-reviewed data concerning the strengths and weaknesses of various studies, including IARC’s own meta-analysis, and is probative to whether the risk of NHL was “known or knowable in light of the scientific knowledge that was generally accepted in the scientific community at the time[.]” Judicial Council Of California Civil Jury Instruction 1205 (Strict products liability).

1 IARC and EPA reports are relevant. Any expert testifying about general causation will, for his  
2 opinion to be admissible, almost certainly need to account for the conclusions reached by these  
3 agencies.”); *see, e.g., Adams v. Cooper Indus., Inc.*, No. CIV.A. 03-476-JBC, 2007 WL 1075647, at  
4 \*4 (E.D. Ky. Apr. 4, 2007) (holding EPA and IARC classifications relevant, not unduly prejudicial,  
5 and admissible for trial). Monsanto, however, raises a concern that the IARC and EPA reviews of  
6 glyphosate might unduly influence the jury on the issue of causation—potentially influencing the jury  
7 to defer to one agency or the other instead of weighing the evidence. *See Mot.* at 7. Fundamentally,  
8 that makes no sense because even the bifurcation Monsanto proposes would necessitate this evidence  
9 for general and specific causation. But even in some artificial world in which it would not be  
10 introduced in evidence, Monsanto’s suggestion is just speculation. Regardless, the solution is *not*  
11 bifurcation; its juror instruction. The Court would simply need to instruct the jury that it may  
12 consider IARC and EPA in assessing the evidence and testimony in this case, but that it should not  
13 *defer* to either agency. Such an instruction would allow the jury to consider the probative value of  
14 IARC and EPA, put in the proper context, and avoid the wholesale exclusion of otherwise relevant  
15 information. After all, even under Rule 403, “[t]rial courts properly are reluctant to exclude relevant  
16 evidence unless there is a powerful and compelling reason to do so.” *In re “Agent Orange” Prod.*  
17 *Liab. Litig.*, 611 F. Supp. 1223, 1255 (E.D.N.Y. 1985).

#### 18 **B. Bifurcation on Causation Creates Structural and Substantive Prejudice**

19 Bifurcation should not be ordered if doing so would prejudice the non-moving party.  
20 *MySpace, Inc. v. Graphon Corp.*, 732 F. Supp. 2d 915, 917 (N.D. Cal. 2010). Here, Monsanto’s  
21 proposal to bifurcate causation creates fundamental structural and substantive prejudice against  
22 Plaintiffs. Structurally, if jurors are told that there will be two phases to the trial, “jurors might  
23 decide in favor of the defendants to avoid having to sit through the second phase.” *Heparin*, 2011  
24 WL 1097637, at \*3, n.1. And, if they are not told about the second phase beforehand, “and return  
25 with a plaintiffs’ verdict, making them unexpectedly have to continue on would be, at best,  
26 unwelcome and probably burdensome.” *Id.* Indeed, it could create considerable hostility within the  
27 jury. This point “is a reason for bifurcating only when clearly appropriate.” *Id.*

28 Moreover, this problem is compounded by the fact that Plaintiffs would be required to recall

1 certain experts and corporate witnesses who will be asked to provide information they had concealed  
2 from the jury during the first phase. This will cause jurors to wonder why, for example, Dr. Portier  
3 did not discuss the EPA’s errors or his participation in IARC panel in the first phase—topics any lay  
4 juror would consider relevant to their task in the first phase—potentially leading jurors to improperly  
5 discredit his testimony during the second phase. And, even if the Court were to instruct the jury to  
6 “not hold it against him or plaintiff” such an instruction, itself, would unfairly cast a cloud over his  
7 testimony.

8 Substantively, if Plaintiffs are prevented from presenting evidence about how Monsanto  
9 influenced and corrupted science and regulators, then the jury will be left with a nagging question—if  
10 this product can cause cancer, why has it been on the market for over forty years with no warning?  
11 This “status quo” defense will infect any causation phase. Plaintiffs have an answer to this question,  
12 but that answer implicates liability evidence. Preventing Plaintiffs from proffering evidence to rebut  
13 this insidious bias—one many jurors will likely bring into the jury box—is severely prejudicial.

#### 14 **C. Separating Probative Causation Evidence from Probative Liability Is Nearly Impossible**

15 Whether issues can be separated is an important consideration in determining whether  
16 bifurcation is justified. Monsanto suggests that evidence relating to causation and damages does not  
17 overlap with liability evidence. But, that is simply not true. There are considerable overlaps between  
18 causation and liability evidence. Here are a few examples:

- 19 • **The Credibility of Monsanto-Generated Science:**

20 A number of studies and publications considered by Plaintiffs’ and Monsanto’s experts in  
21 rendering their opinions were created or generated by Monsanto. Monsanto’s wrongful conduct  
22 related to those studies goes to credibility of that data and, in turn, the experts’ opinions. For  
23 example:

- 24 ○ In one early long-term carcinogenicity rodent study paid for by Monsanto, EPA scientists  
25 unanimously concluded it showed that glyphosate was oncogenic, i.e., caused tumors.  
26 However, in response to this finding, Monsanto paid a doctor to find a tumor in the control  
27 group—a tumor no pathologist had ever seen—and that tumor undermined the EPA’s finding.  
28 Plaintiffs have evidence that this “magic” tumor was fabricated by Monsanto’s consultants

1 and used to mislead the EPA and, ultimately, the academic community. Remarkably, when  
2 the EPA requested that Monsanto redo the study, so that the controversy over this “magic”  
3 tumor could be resolved, Monsanto refused—indeed, it has not been done to this day.

- 4 ○ There is evidence that Monsanto commissioned a dermal absorption study by TNO  
5 Laboratories. Monsanto was hoping to show 3% or less dermal absorption. The early findings  
6 of the study showed a staggering 10% absorption rate in formulated product. At that point,  
7 Monsanto terminated the study, worried that it would undermine Monsanto’s corporate  
8 objectives. Monsanto also accused TNO of doing the study poorly. So, TNO offered to redo  
9 the study, for free. Monsanto refused. The results of the study were then buried and never  
10 submitted to agencies or Monsanto’s experts. Monsanto’s various admissions about the  
11 results of the test are relevant to refuting Monsanto’s exposure expert and supporting  
12 Plaintiffs’.

- 13 • **Monsanto’s Admissions:**

14 Because Monsanto developed, researched, and sold Roundup for over forty years, as a  
15 company it *should* know more about the product’s safety than anyone else. However, there are  
16 numerous documents and associated testimony, wherein Monsanto scientists make admissions about  
17 causation and the underlying studies. For example:

- 18 ○ Dr. Donna Farmer admits, on multiple occasions, that Monsanto cannot say that Roundup  
19 does not cause cancer because Monsanto has not done the necessary testing on formulated  
20 Roundup. In assessing whether the scientific evidence is sufficient to show causation, the  
21 jury should be allowed to know that Monsanto, for over a decade, has refrained from studying  
22 the formulated product in laboratory settings.
- 23 ○ At various points, Dr. Farmer makes admissions regarding epidemiology and genotox studies  
24 and provides opinions about the importance and content of those studies. She also, in early  
25 2000s, attacks the Agricultural Health Study as being “junk science” and inaccurate, when she  
26 believes it will reveal a risk for glyphosate. This stands in contrast to her testimony about the  
27 AHS today.
- 28 ○ Dr. William Heydens admitted in 2014, upon learning that IARC was going to review

1 glyphosate, that Monsanto is vulnerable in epidemiology, toxicology, and mechanism, and  
2 that IARC could string the evidence together to find a risk. Dr. Heydens' (and others)  
3 anticipation of a carcinogenicity classification from IARC, provides circumstantial evidence  
4 that Monsanto knew glyphosate and Roundup were carcinogenic.

- 5 ○ In 1999, Monsanto commissioned a report by Dr. James Parry to review the genotoxicity of  
6 glyphosate and Roundup. Dr. Parry reviewed the data and concluded that glyphosate and  
7 Roundup were clastogenic, i.e., mutagenic by causing breakages of chromosomes. Dr. Parry  
8 recommended numerous studies that Monsanto should conduct to explore this problem. In  
9 response, various Monsanto employees acknowledge his findings, express concern about its  
10 implications, and decide they will not do the studies Dr. Parry recommends. Monsanto, in  
11 turn, buries the report and does not send it to any regulator.
- 12 ○ Daniel Jenkins worked with the EPA's Jess Rowland to "kill" the US Agency for Toxic  
13 Substances and Disease Registry ("ATSDR") review of glyphosate because they were  
14 concerned that ATSDR would reach conclusions like IARC's. Dr. Rowland later went on to  
15 draft the EPA's recent report on glyphosate. He also spread a false rumor that one of mouse  
16 studies that showed elevated rates of malignant lymphoma in the glyphosate-exposed mice  
17 (Kumar), was infected with a virus. Later review, by other scientists, confirmed there is no  
18 evidence of a virus. Monsanto's experts still spout this false virus theory.
- 19 ○ Dr. Daniel Goldstein testified on behalf of Monsanto, that positive findings in case-control  
20 epidemiology studies are likely spurious, going so far as to testify that its more likely that  
21 coffee causes spontaneous abortion than a pesticide causes cancer.

- 22 • **Monsanto's Manipulation of Science:**

23 There is considerable evidence that Monsanto engaged in various forms of scientific  
24 manipulation, including ghostwriting and academic bullying. These actions have infected the body of  
25 scientific work considered by the Parties' experts, regulatory agencies, and overall academic  
26 community. In this context, the line between "liability" and "causation" evidence does not exist.

- 27 ○ Dr. William Heydens stated in an email that Monsanto ghost-authored the Williams, Kroes, &  
28 Munro (2000) article, which for approximately a decade served as the seminal piece about



1 glyphosate and Roundup's genotox profile. Plaintiffs also have the various drafts and emails  
2 by Dr. Heydens relating to the development of the article. This article was published  
3 immediately after Monsanto secretly received (and then buried) a report, about the same  
4 topics, from Dr. Parry (discussed above). All of Monsanto's experts rely on the Williams  
5 article, and it is frequently cited in peer-reviewed epidemiology studies published on  
6 glyphosate and Roundup, as a "counter" to their positive findings. For example, in De Roos  
7 2003, the authors conclude their "findings provide some impetus for further investigation into  
8 the potential health effects of glyphosate, even though one review concluded that the active  
9 ingredient is non-carcinogenic and non-genotoxic." (citing Williams). Thus, this ghost-  
10 authored paper, which reflects misconduct by Monsanto, is woven into the issue of causation.  
11 There are numerous other examples of ghost-authorship, with similar ties to causation.

- 12 ○ In 2012, Monsanto orchestrated an attack against Dr. Gilles-Éric Séralini for publishing the  
13 results of a two-year feeding study in rats, which reported an increase in tumors among rats  
14 fed genetically modified corn and Roundup. The study was originally designed by Monsanto  
15 as a short-term analysis and, in turn, its protocol was adopted by Dr. Séralini but for a period  
16 extending to the full life time of rats. Monsanto orchestrated a letter campaign, careful not to  
17 show its hand, to make it look like it was independent scientists conveying criticism of  
18 Séralini's study. Then, Monsanto recruited the editor of the journal to be a paid "consultant"  
19 who, a few weeks later, retracted the study. It was subsequently republished in another  
20 journal. The reliability of the study was questioned by both Plaintiffs' and Monsanto's  
21 experts, but recent revelations and publications about the study have brought its relevance into  
22 new light, and it is evidence the jury should consider, through the testimony of Monsanto's  
23 corporate witnesses, Monsanto's experts, and third-party witnesses. The Séralini affair is one  
24 of many examples where Monsanto attempted to intimidate independent scientists.
- 25 ○ When glyphosate was originally approved for use in 1974, Monsanto submitted the results of  
26 a single long-term mouse oncogenicity study. That study was conducted by Industrial Bio-  
27 Test Laboratories, Inc. ("IBT"). At the time, a former Monsanto toxicologist, Paul Wright,  
28 worked at IBT overseeing toxicology. Then, after IBT's oncogenicity test on glyphosate was

1 submitted to the EPA, Dr. Wright returned to Monsanto. *United States v. Keplinger*, 776 F.2d  
 2 678, 684 (7th Cir. 1985). A few years later, Dr. Wright was indicted for creating fraudulent  
 3 science while at IBT and, after a six-month trial, found guilty. *Id.* at 683-84. It is Plaintiffs’  
 4 understanding that Dr. Wright remained employed by Monsanto during his criminal  
 5 prosecution. Upon learning of this fraud, EPA declared the study invalid and requested that  
 6 Monsanto redo it. It was not until 1983, a decade after Roundup first entered the market, that  
 7 Monsanto submitted a new study (the one that involved the “magic tumor” described above).  
 8 Remarkably, despite this well-known fraud, Monsanto’s experts, to this day, rely on IBT data.  
 9 The IBT fiasco, therefore, is relevant to Monsanto’s experts’ credibility.

10 • **Credibility of Plaintiffs’ Experts:**

11 Evidence showing Monsanto’s extreme efforts to suppress scientific development are also  
 12 relevant to assessing Plaintiffs’ experts’ credibility. For example, in *Johnson*, Monsanto argued:

13 Dr. Portier not only disagreed with everybody, but thought that everybody was  
 14 astonishing wrong, amazingly wrong, completely wrong, totally illogical.  
 15 Everybody in the world except Dr. Portier is astonishing, illogical, completely  
 16 wrong, amazingly wrong. ECHA, EFSA, BfR, EPA ...

17 Now, does that sound like a guy who is an objective expert? Is that the way an  
 18 objective expert would talk about people? And it ends up that Dr. Portier actually  
 19 has skin in the game. Dr. Portier is not objective at all. He’s part of the story of this  
 20 case. He was at IARC as an invited observer, not a participant. Very shortly  
 21 thereafter, he was hired by plaintiff’s lawyers, and since then, he’s been going  
 22 around pushing his theory of glyphosate unsuccessfully.

23 ... So Dr. Portier is a partisan in the process. Dr. Portier is part of the story of this  
 24 case. He’s not an objective outside observer. And I ask that you consider that when  
 25 you evaluate his credibility.

26 Exh. 2, Tr. Closing Arguments, *Johnson v. Monsanto*, at 5178-80 (emphasis added). Monsanto  
 27 intends to attack the credibility of Plaintiffs’ experts, like Dr. Portier, by characterizing them as an  
 28 apostate to the scientific community. How Monsanto has helped cultivate, manipulate, and fabricate  
 that “scientific” community is, therefore, highly relevant to Dr. Portier’s credibility—in whatever  
 phase it is challenged. Similarly, the findings by IARC and Monsanto’s reaction to it help elucidate  
 whether Dr. Portier, or any of Plaintiffs’ experts, are truly outside of the “mainstream” of scientific  
 knowledge. Trying to unpack these issues and confine them to separate phases of a trial is not viable.

• **Plaintiffs’ Treating Doctors:**

1 One of Monsanto's defenses in refuting specific causation focuses on the plaintiff's treating  
 2 physicians and attempting to characterize Plaintiffs' specific-cause expert as an outlier. Here is how  
 3 that played out in the *Johnson* trial:

4 We also talked about Mr. Johnson's treating doctors. ... These are the people who  
 5 know Mr. Johnson the best. ....

6 And not one of these people, not one of these people, told Mr. Johnson that his  
 7 cancer was caused by [Roundup]. ... There's only one medical doctor you heard  
 8 from that purported to know the cause of mycosis fungoides. And that was Dr.  
 9 Nabhan. ... And how did he come to that conclusion? ... what he said was, "I'm  
 10 just going to go through every risk factor I can think of for mycosis fungoides. And  
 11 I eliminated everything," he said. "I eliminated all of these except for Roundup." ...  
 If it were that easy, why didn't we figure it out a long time ago? ... [I]f Dr. Nabhan  
 is actually the guy ... this would be a huge medical accomplishment, discovering  
 the cause of mycosis fungoides, the first person in the world to do that. If Dr.  
 Nabhan had actually done that, wouldn't he have been in here showing you an  
 article telling the scientific community about it? Wouldn't he be collecting awards  
 for having done it?

12 Exh. 2, Tr. Closing Arguments, *Johnson v. Monsanto*, at 5159-63. This attack on Dr. Nahban's  
 13 credibility is a species of the "40 years of safety" argument because it assumes the status quo is right  
 14 and anything going against it, i.e., Plaintiffs' experts, is wrong. The only way to rebut this attack and  
 15 explain why treating physicians do not know about the risk of Roundup, is to explain that Monsanto  
 16 has systematically suppressed the dissemination of this information within the medical community.  
 17 Monsanto would undoubtedly argue that bifurcation precludes Plaintiffs from offering that evidence.

18 Plaintiffs could go on for over a hundred pages, explaining the various ways liability evidence  
 19 and causation evidence overlap and the difficulty, if not impossibility, of untangling this evidence  
 20 into two phases of a trial. What is more, bifurcation would require rulings by this Court for nearly  
 21 every piece of evidence to determine whether a piece of evidence could be used in one phase or the  
 22 other, or both. The sheer amount of time spent engaging in those nuanced arguments—distinct from  
 23 whether any evidence is generally admissible—would eviscerate any potential efficiency.

#### 24 **D. Bifurcation Defies Judicial Efficiency and Economy**

25 Finally, bifurcation means that a four-week trial becomes two trial phases lasting six. It  
 26 would also increase the cost of the trial as many, if not most, of the same witnesses would be called  
 27 in both phases. There is nothing efficient or economical in bifurcating the Group 1 Plaintiffs.

#### 28 **CONCLUSION**

For the foregoing reasons, Plaintiffs respectfully request that the Court deny bifurcation.

1 DATED: December 13, 2018

Respectfully submitted,

2 By: /s/ R. Brent Wisner

3 R. Brent Wisner, Esq. (SBN: 276023)

[rbwisner@baumhedlundlaw.com](mailto:rbwisner@baumhedlundlaw.com)

4 BAUM, HEDLUND, ARISTEI, & GOLDMAN, P.C.

10940 Wilshire Boulevard, 17th Floor

5 Los Angeles, CA 90024

Telephone: (310) 207-3233

6 Facsimile: (310) 820-7444

7 Aimee Wagstaff

[aimee.wagstaff@andruswagstaff.com](mailto:aimee.wagstaff@andruswagstaff.com)

8 ANDRUS WAGSTAFF, P.C.

7171 West Alaska Drive

9 Lakewood CO 80226

10 Telephone: (303) 376-6360

Facsimile: (303) 376-6361

11 Robin Greenwald

[rgreenwald@weitzlux.com](mailto:rgreenwald@weitzlux.com)

12 WEITZ & LUXENBERG, P.C.

700 Broadway

13 New York NY 10003

14 Telephone: (212) 558-5500

Facsimile: (212) 344-5461

15 Michael Miller

[mmiller@millerfirmllc.com](mailto:mmiller@millerfirmllc.com)

16 THE MILLER FIRM, LLC

17 108 Railroad Ave

Orange VA 22960

18 Telephone: (540) 672 4224

19 Facsimile: (540) 672-3055

20 *Attorneys for Plaintiffs*

**CERTIFICATE OF SERVICE**

I certify that I have served a copy of the foregoing PLAINTIFFS' OPPOSITION TO ISSUE BIFURCATION upon all opposing counsel of record by electronic mail and/or by placing a copy of same in the U.S. Mail, first class, postage prepaid, this 13th day of December, 2018.

By: /s/ R. Brent Wisner  
R. Brent Wisner, Esq. (SBN: 276023)  
[rbwisner@baumhedlundlaw.com](mailto:rbwisner@baumhedlundlaw.com)  
BAUM, HEDLUND, ARISTEI, & GOLDMAN, P.C.  
10940 Wilshire Boulevard, 17th Floor  
Los Angeles, CA 90024  
Telephone: (310) 207-3233  
Facsimile: (310) 820-7444

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

# EXHIBIT 1

# 10

7/9

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

1. What is the surfactant? Nevermind / answered. - POEA.
2. Data on POEA? show how it gets through skin? (human skin)
3. in ~~an~~ animal studies, how glyphosate formulated? what is the vehicle?
4. How was ranch study (rat) conducted? as compared to others?
5. Clarify glyphosate's Meth of Action (MOA) → does it bind to an enzyme rendering the enzyme nonfunctional?  
~~or is the enzyme not needed at all?~~ does it compete with another substrate?
6. how are micronuclei related to cancer? supporting data?
7. What are the epi studies? people who used roundup? people exposed or in proximity to?
8. Was IARC making unanimous decision abt glyphosate or glyphosate + surfactant?  
assuming glyphosate but good to clarify since discussing both and the formulation in particular.  
↳ did they also test old formulations?

~~9. ...~~

This \_\_\_\_\_ day of \_\_\_\_\_, 2018  
Time: \_\_\_\_\_ AM / PM Juror Seat Number \_\_\_\_\_

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

1. in DeRozos 2005 study, is it known what the exposure is? how many uses, did users get on body?  
Same for Napp → what are the exposures? acute/chronic/mix?  
2018 data broken into exposure groups?
2. Has POEA been used in combo w/ other compounds that do or do not cause cancer? Any evidence for surfactant + compound combinations? <sup>POEA</sup>
3. does glyphosate based formulations mean the final formulation in the product?
4. What is Mr. Johnson's exposure in mg/kg? (estimation if were to get a large dose on skin)
5. How know Mr. Johnson's cancer started before exposure? Test results / data?
6. What is statistical risk of mycosis fungoides in African Americans (Ranger Pro and not ranger pro groups)?

This 9th day of July, 2018  
Time: \_\_\_\_\_ AM/PM

10  
Juror Seat Number



SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

- ① Given prior lawsuits filed, why is this the first case to come before a jury?
- ② Why is this case in SF Superior Court, since plaintiff is from Richmond?
- ③ Does the plaintiff have to prove that his cancer was caused by the use of Ranger Pro? If he developed his cancer before exposure to Ranger Pro and his cancer was worsened by that exposure, is that sufficient to decide for the plaintiff? (After consideration of all testimony and evidence, and if the jury so decides, of course.)
- ④ Can you require the expert witnesses for both sides to disclose if they are receiving any compensation (direct, research funding, etc.) for their testimony? And any past funding (last 20 yrs).

\*Sorry for my poor handwriting. Decades of ~~handwriting~~ writing via keyboard has led to deteriorating ~~legibility~~ legibility. Actually - my writing was always close to illegible.

This 9<sup>th</sup> day of July, 2018  
Time: \_\_\_\_\_ AM/PM

1  
Juror Seat Number

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

What is the difference between pesticide and an herbicide?

Do humans have EPSPS enzyme?

Did plaintiff reuse drenched clothing?

This 9 day of July, 2018  
Time: 4:30 AM/PM

15  
Juror Seat Number

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

**JURY NOTE**

QUESTION(s):

1) Can we get clarification on which product(s)  
Mr. Johnson used? Ranger Pro vs. Roundup

2) Will the product label be introduced as evidence (for  
the product he actually used)?

This 9<sup>th</sup> day of July, 2018  
Time: \_\_\_\_\_ AM/PM

8  
Juror Seat Number

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

What product(s) are banned in Europe?  
Glyphosate or Round-Up/Ranger Pro? Why?

Why didn't Goldstein call back as he  
stated that he would?

What were the controls in "Genotoxic Potential  
of Glyphosate Formulation" - publication ~~by~~ which  
included D. Farmer & Heydens?

This 10<sup>th</sup> day of July, 2018  
Time: 9:40 (AM) PM

#9  
Juror Seat Number

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

Who is Responsible for the equipment that failed  
Did Mr. Johnson immediately Remove his wet clothing  
& take a shower to get Rangee Pro off his skin?

Did he notify his employer & what was  
his employers Response

Why didn't Monsanto useply to his phone  
calls immediately?

Even if the EPA did not specifically Ask for  
Roundup as a whole to be tested, Why didn't  
Monsanto do it for itself & its customers?

Is the Round-up for mutation different  
in the European Union And in the USA?

This 10 day of July, 2018  
Time: \_\_\_\_\_ AM/PM

13  
Juror Seat Number

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

*Please clarify for whom Dr. Portier evaluated  
the studies depicted in exhibits 1020, 1021.*

This \_\_\_\_\_ day of \_\_\_\_\_, 2018  
Time: \_\_\_\_\_ AM / PM

4  
Juror Seat Number

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

1. CDI mouse - are these mice more prone to cancer than other strains?
2. ~~control animals given vehicle~~ → were control animals given vehicle solvent alone? were they given what glyphosate was formulated or dissolved in?
3. In any of the animal studies was the highest dose at MTD?

This \_\_\_\_\_ day of \_\_\_\_\_, 2018  
Time: \_\_\_\_\_ AM / PM

10  
Juror Seat Number

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

Can a "key" please be added to chart to  
explain what the symbols mean?  
For example, what the \* means

This 12 day of July, 2018  
Time: 1:20 AM/PM

15  
Juror Seat Number



SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

How would AHS numbers/results (RR)  
be affected if a percentage of those who  
would have responded, passed away from  
some form of NHL?!

How do scientist justify placing their names  
on conflicting studies/data?  
De Roos  
Andreotti

This 18 day of July, 2018  
Time: 3 AM/PM

9  
Juror Seat Number

**COPY**

COPY

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

What is the general progression and time frame of ~~the~~ NHL?  
Are there different stages?  
How long does a patient typically start manifesting NHL before it  
is diagnosed?

This 20 day of July, 2018  
Time: \_\_\_\_\_ AM/PM

16  
Juror Seat Number

**COPY**

**SUPERIOR COURT OF CALIFORNIA  
County of San Francisco**

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

**JURY NOTE**

QUESTION(s):

If the 2mg/kg/day risk reference dose does not have anything to do with carcinogenicity, what does this dose measure for?

This \_\_\_\_\_ day of \_\_\_\_\_, 2018  
Time: \_\_\_\_\_ AM/PM

15  
Juror Seat Number

JUL 26 2018  
2:08 PM

COPY

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

JURY NOTE

QUESTION(s):

How long is the latency period for the squamous cell carcinoma plaintiff developed on his leg?

This 26 day of July, 2018  
Time: 1:40 AM/PM

16  
Juror Seat Number

**COPY**

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

**JURY NOTE**

QUESTION(s):

1) Is the estimate of end of trial still accurate at August 10? If not, can we have a revised estimate?

&

2) Can we ask Mr. Lombardi to keep his voice down during cross examination? Since he repositions the podium, tends to shout at the jury as well as witness

This 26 day of July, 2018

Time: 10:43 AM PM

14  
Juror Seat Number

**COPY**

**SUPERIOR COURT OF CALIFORNIA  
County of San Francisco**

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

**JURY NOTE**

QUESTION(s):

Does RoundUp / Ranger Pro's product labeling state to stop using if skin irritation occurs?

Was Johnson advised by Biehl or a Poison Control Center call (03/2015) to stop / cease using RoundUp / Ranger Pro?

This 16 day of July, 2018  
Time: 3:30pm AM / PM

9  
Juror Seat Number

**COPY**

**SUPERIOR COURT OF CALIFORNIA  
County of San Francisco**

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,

Plaintiff,

vs.

MONSANTO COMPANY,

Defendant.

Case Number: CGC-16-550128

**JURY NOTE**

**QUESTION(s):**

Video deposition of Kirk Acevedo = he said he joined Monsanto because of the philosophy of Robert Shapiro. Who was this and what was that philosophy?

Stipulation of Monsanto net worth = \$6.6 B.

Before this trial, I thought Monsanto was sold for a higher amount. Can we know the buyer and sales price?

This 27<sup>th</sup> day of July, 2018

Time: 4:00 AM/PM

1  
Juror Seat Number

**COPY**

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

**JURY NOTE**

QUESTION(s):

For the alternates, can we be notified when the verdict will be read and be given a pass to be in the court room?

This 2 day of August, 2018  
Time: 4:30 AM/PM

16  
Juror Seat Number



**COPY**

SUPERIOR COURT OF CALIFORNIA  
County of San Francisco

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

**JURY NOTE**

QUESTION(s):

1- What is the "usual" amount of time  
from when a study is completed and  
when it is published?

This 2 day of Aug, 2018  
Time: \_\_\_\_\_ AM/PM

13  
Juror Seat Number

**COPY**

**SUPERIOR COURT OF CALIFORNIA**  
**County of San Francisco**

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128


**JURY REQUEST FORM**

Question # 3

WE, the jury in the above-entitled action, request the following:

~~WISPER~~ 1) Transcripts on historical controls for  
Dr. Foster during direct and redirect, X and recross  
— specifically discrepancy between historical  
controls in the CD-1 mouse studies  
Time: Aug 2, towards end of direct

This 9 day of August, 2018

  
Presiding Juror

Time: 1:35 AM (PM)

For Court Use:

Dated \_\_\_\_\_

HON. SUZANNE R. BOLANOS  
Judge of the Superior Court

**COPY**

**SUPERIOR COURT OF CALIFORNIA**  
**County of San Francisco**

Honorable SUZANNE R. BOLANOS, Judge Presiding  
Department 504

DEWAYNE JOHNSON,  
Plaintiff,  
vs.  
MONSANTO COMPANY,  
Defendant.

Case Number: CGC-16-550128

**JURY REQUEST FORM**

Question # 2


WE, the jury in the above-entitled action, request the following:

1) Can someone define "ordinary consumer" on the verdict form

2) May we see a written copy of the stipulations and admissions?

This 9 day of August, 2018

Time: 9:40 AM PM

  
Presiding Juror

For Court Use:

Dated \_\_\_\_\_

HON. SUZANNE R. BOLANOS  
Judge of the Superior Court

# EXHIBIT 2

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

SUPERIOR COURT OF THE STATE OF CALIFORNIA  
COUNTY OF SAN FRANCISCO

DEWAYNE JOHNSON,

Plaintiff,

vs.

Case No. CGC-16-550128

MONSANTO COMPANY, et al.,

Defendants.

-----/

Proceedings held on Tuesday, August 7, 2018,  
Volume 25, Afternoon Session, before the Honorable  
Suzanne R. Bolanos, at 1:44 p.m.

REPORTED BY:

LESLIE ROCKWOOD ROSAS, RPR, CSR 3462

Job No. 2983883B

Pages 5130 - 5249

1 to give cancer patients some idea of why they were the  
2 unlucky ones, the truth is you frequently just can't do  
3 that.

14:22:10 4 And that's what Dr. Kuzel told you. Dr. Kuzel  
5 said every case of mycosis fungoides is of unknown  
6 etiology. Etiology means unknown origins, unknown cause.

7 Asked about what was the conclusion about the  
8 most likely cause of Mr. Johnson's mycosis fungoides,  
9 same conclusion he has for everybody else with mycosis  
14:22:29 10 fungoides. "We don't know why they get mycosis  
11 fungoides." It would be nice to be able to tell people  
12 it's something, but you just can't do it. And that's  
13 what Dr. Kuzel told you.

14 Dr. Kuzel, remember, he is a guy who said he was  
14:22:45 15 at a tertiary care facility. That means that people come  
16 from all over -- they're referred to him -- about mycosis  
17 fungoides. He's written numerous articles. I think 75  
18 articles just on mycosis fungoides alone. He's written  
19 book chapters on mycosis fungoides. He's sought out for  
14:23:03 20 that.

21 We also talked about Mr. Johnson's treating  
22 doctors. And this isn't all of them. You heard about a  
23 lot of them from the medical records. There's a lot of  
24 discussion in the medical records. And all of these  
14:23:18 25 folks were mentioned in the medical records. And

1 Mr. Johnson had an outstanding group of doctors -- has an  
2 outstanding group of doctors who work with him.

3           You had the opportunity to meet Dr. Ofodile, who  
4 was nice enough to come here to testify before you,  
14:23:33 5 Dr. Pincus is at UCSF, Dr. Tsai, I believe is Kaiser  
6 Permanente. Dr. Kim and Dr. Hoppe are at Stanford. And  
7 one thing about those two, they, like Dr. Kuzel, are  
8 luminaries in the world of mycosis fungoides. They are  
9 the world's experts. They've written about mycosis  
14:23:54 10 fungoides. They know what it's all about.

11           These are the people who know Mr. Johnson the  
12 best. They know his disease the best. They're the ones  
13 that have actually treated him. These are the people who  
14 also know the actual disease, mycosis fungoides, better  
14:24:11 15 than anybody.

16           And not one of these people, not one of these  
17 people, told Mr. Johnson that his cancer was caused by  
18 mycosis fungoides. Now, I think Counsel said it would be  
19 a lie if I said that.

14:24:27 20           Let's go to Slide 567 -- excuse me. Slide 686.  
21 I'm sorry.

22           This is Dr. Nabhan. He'd reviewed all of the  
23 depositions of all of the treating doctors. "As you went  
24 through the records and you went through the depositions,  
14:24:41 25 you noted that each of them came to the conclusion that

1 they didn't know what caused mycosis fungoides; is that  
2 right?" And he agreed with that.

3 It's not a lie. It's a fact. There's fact and  
4 there's argument.

14:24:55 5 So if we could go back to 567, please.

6 So who is the -- who's the dissenter that you've  
7 heard from in this group? There's only one medical  
8 doctor you heard from that purported to know the cause of  
9 mycosis fungoides. And that was Dr. Nabhan.

14:25:19 10 And Dr. Nabhan is a retired practicing doctor.  
11 He used to practice medicine. About two years ago he  
12 stopped practicing medicine, and he moved to a Fortune 15  
13 healthcare company called Cardinal Health. And he's now  
14 a business executive there.

14:25:41 15 And Dr. Nabhan's role in this case was to meet  
16 with Mr. Johnson. So Mr. Johnson actually, while sick,  
17 flew from here out to Chicago to meet with Dr. Nabhan in  
18 his corporate office for one hour. One hour.

19 And in that meeting in that corporate office,  
14:26:04 20 they talked. There was no blood work. There was no  
21 trying to figure out anything about his cells or anything  
22 like that. It was just talk.

23 And then Dr. Nabhan decided that he'd read  
24 some -- he'd read some materials. And he came to the  
14:26:25 25 conclusion that Mr. Johnson's mycosis fungoides was



1 actually caused by glyphosate.

2           So Dr. Nabhan said that he treated mycosis  
3 fungoides patients. He treated far fewer than Dr. Kuzel,  
4 but he said he treated some. And he said that he didn't  
14:26:45 5 come to the conclusion that anybody's mycosis fungoides  
6 was caused by glyphosate until after he was retained in  
7 this litigation, which was after he stopped practicing  
8 medicine.

9           So he never ever told anybody that mycosis  
14:27:00 10 fungoides was caused by glyphosate while he was actually  
11 dealing with patients. It's only after he got involved  
12 in this case that he came to that conclusion.

13           And how did he come to that conclusion? This is  
14 how: We've put up -- we've actually tried to recreate  
14:27:20 15 his board. He actually did this in his own handwriting,  
16 and so we took the transcript of the trial and, kind of,  
17 wrote it out.

18           But what he said was, "I'm just going to go  
19 through every risk factor I can think of for mycosis  
14:27:36 20 fungoides. And I eliminated everything," he said. "I  
21 eliminated all of these except for Roundup." Well,  
22 Ranger Pro. "And because I eliminated everything but  
23 Roundup or Ranger Pro, then Ranger Pro must have been the  
24 cause." Then Ranger Pro must have been the cause.

14:27:52 25           Now, let's just take a step back for a second.

1 If it was that easy to figure out the cause of mycosis  
2 fungoides, why do all the doctors that are actually  
3 treating doctors saying, "We don't know the cause"?

14:28:08 4 If it were that easy, why didn't we figure it  
5 out a long time ago? If it were that easy, if Mr. -- if  
6 Dr. Nabhan is actually the guy -- remember, this would  
7 be -- this would be a huge medical accomplishment,  
8 discovering the cause of mycosis fungoides, the first  
9 person in the world to do that.

14:28:25 10 If Dr. Nabhan had actually done that, wouldn't  
11 he have been in here showing you an article telling the  
12 scientific community about it? Wouldn't he be collecting  
13 awards for having done it?

14 So you should be questioning how it is that  
14:28:44 15 somebody who leaves the practice of medicine all of the  
16 sudden comes to the conclusion, based on reading some  
17 documents and meeting with Mr. Johnson for an hour, that  
18 glyphosate causes cancer. You should think about that.

19 But Dr. Kuzel said the problem with this -- the  
14:29:05 20 problem with this whole analysis is he left one important  
21 thing off the list. Remember? Everything says that  
22 mycosis fungoides is of unknown cause. He didn't  
23 consider the possibility that Mr. Johnson's was due to an  
24 unknown cause. Totally left it off his list. Totally  
14:29:23 25 left it off his list.

1 biostatistician, but he says he's an expert on  
2 everything.

3           What's it mean when Dr. Nabhan, who's now a  
4 businessman but was a medical doctor, says he's an expert  
14:50:01 5 on epidemiology? He can tell you about the epidemiology.  
6 He can tell you about the mouse tests.

7           We brought you experts, real experts, Dr. Mucci,  
8 Dr. Foster. We brought you real experts, Dr. Kuzel, in  
9 their field to talk to you about these areas. And you  
14:50:18 10 might have noticed the difference in the way they acted  
11 on the witness stand. When they were asked questions by  
12 us, they answered the questions, and when they were asked  
13 questions by the other side, they answered the questions.  
14 There wasn't a lot of spinning. There wasn't a lot of  
14:50:34 15 arguing. They answered the questions. They were here to  
16 provide you with their expertise, and what did that  
17 expertise show? It showed that glyphosate doesn't cause  
18 cancer.

19           But let's talk for a second about Dr. Portier,  
14:50:48 20 because Dr. Portier, I think, is a special case.  
21 Dr. Portier not only disagreed with everybody, but  
22 thought that everybody was astonishingly wrong, amazingly  
23 wrong, completely wrong, totally illogical. Everybody in  
24 the world except Dr. Portier is astonishing, illogical,  
14:51:13 25 completely wrong, amazingly wrong. ECHA, EFSA, BfR, EPA.

1 Now, does that sound like a guy who is an  
2 objective expert? Is that the way an objective expert  
3 would talk about people? And it ends up that Dr. Portier  
4 actually has skin in the game. Dr. Portier is not  
14:51:35 5 objective at all. He's part of the story of this case.  
6 He was at IARC as an invited observer, not a participant.  
7 Very shortly thereafter, he was hired by plaintiff's  
8 lawyers, and since then, he's been going around pushing  
9 his theory of glyphosate unsuccessfully. Unsuccessfully.

14:51:57 10 And so when Dr. Portier talks about his theory  
11 of glyphosate, understand that Dr. Portier, his view has  
12 been rejected by the EPA, the EFSA, the ECHA and the BfR,  
13 all of those entities you heard about. All of those  
14 entities you heard about. He's not an objective source.

14:52:18 15 And when plaintiffs say -- I've lost my side.

16 When plaintiffs say that Dr. Portier has support  
17 in the entire scientific community, remember what you  
18 heard in the evidence. Dr. Portier sent out emails. He  
19 tried to generate support from people. He sent out an  
14:52:39 20 email to 500 scientists asking them for their signatures.  
21 Now, he got something like 70 or 90 signatures, but the  
22 vast majority of the scientists he reached out to  
23 wouldn't sign on to what he did.

24 So Dr. Portier is a partisan in the process.  
14:52:55 25 Dr. Portier is part of the story of this case. He's not

1 an objective outside observer. And I ask that you  
2 consider that when you evaluate his credibility.

3           Let's talk about IARC, because IARC really is  
4 plaintiff's case. Without IARC, they have nothing. They  
14:53:17 5 rely completely on IARC to try to make you believe that  
6 Mr. Johnson's cancer was caused by glyphosate, and  
7 they've been very critical of Monsanto for being  
8 concerned in advance of the IARC decision about what the  
9 result might be, but this is what -- and this is  
14:53:36 10 undisputed in the evidence. This is what Monsanto knew.  
11 This is what Monsanto knew. These are the various  
12 categories that you can get when you are evaluated, when  
13 an agent is evaluated by IARC. It goes from carcinogenic  
14 all the way down to probably not carcinogenic, so here's  
14:53:51 15 what Monsanto knew.

16           You have literally, if IARC decides to consider  
17 a chemical, a 1 in 1,000 chance that you're going to be  
18 in Group 4. Literally a 1 in 1,000 chance that it's  
19 going to be considered probably not carcinogenic.

14:54:08 20           How about Group 3? This is not classifiable  
21 because there's not enough information. Now, how in the  
22 world would anybody conclude that there's not enough  
23 information about glyphosate? It's been around for  
24 40 years, so, yeah, Monsanto was concerned when  
14:54:23 25 glyphosate was taken up by IARC and with good reason.